Merck Animal Health Acquires US Rights to SENTINEL Brand of Combination Parasiticides for Companion Animals

- July 2nd, 2020

Merck Animal Health today announced the completion of its previously announced acquisition of the US rights to Sentinel Flavor Tabs and Sentinel Spectrum Chews in the companion animal category from Virbac.

Further Solidifies Merck Animal Health’s Position in the U.S. Companion Animal Category with Comprehensive, Continuous Parasite Protection

Complements Merck Animal Health’s Broad Portfolio of Vaccines and Pharmaceuticals

Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), today announced the completion of its previously announced acquisition of the U.S. rights to SENTINEL® FLAVOR TABS® and SENTINEL® SPECTRUM® Chews in the Companion Animal category from Virbac (NYSE Euronext:VIRP).

Comprehensive parasite protection is an essential part of canine overall health and well-being. “Our veterinary medicines, including parasiticides, and vaccines continue to transform the animal health industry and further solidify our position in the U.S. Companion Animal category,” said Rick DeLuca, president, Merck Animal Health. “The extensive breadth and depth of our product portfolio enhances our offerings of comprehensive pet care solutions, which provide a full range of complementary solutions for our customers to improve the health and well-being of animals and the people who care for them.”

About Merck Animal Health

For more than a century, Merck, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, is the global animal health business unit of Merck. Through its commitment to The Science of Healthier Animals®, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of digitally connected identification, traceability and monitoring products. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com or connect with us on LinkedIn, Facebook, and Twitter at @MerckAH.

About Virbac

Virbac offers veterinarians, farmers and pet owners in more than 100 countries a practical range of products and services for diagnosing, preventing and treating the majority of diseases while improving quality of life for animals. With these innovative solutions covering more than 50 species, Virbac contributes day after day to shaping the future of animal health.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2019 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

Merck Media:

Noreen Verbrugge

+ 1 (973) 937-5450

Noreen.Verbrugge@merck.com

Pam Eisele

+1 (267) 305-3558

Pamela.Eisele@merck.com

Merck Investors:

Michael DeCarbo

+ 1 (908) 740-1807

Michael.DeCarbo@merck.com

Copyright Business Wire 2020
Business Wire
July 1, 2020 – 11:00 PM PDT
News by QuoteMedia

Should you invest in the 2020 pharmaceutical market?

Read our FREE outlook report!
 

Tags

Tags: ,

Leave a Reply